Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Entolimod (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 15 May 2017 According to a Cleveland BioLabs media release, dosing has been completed in this trial.
- 08 Feb 2017 Planned End Date changed from 1 Nov 2016 to 31 Dec 2017.